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Interferon gamma release assay
QuantiFERON-TB Gold In-Tube
S U M M A R Y
Background: The impact of anti-tuberculosis treatment with and without antiretroviral therapy (ART) on
standardized interferon gamma release assay (IGRA) readouts has been studied inadequately in high-
burden countries.
Methods: The QuantiFERON-TB Gold In-Tube (QFT-GIT) test was used to evaluate interferon gamma
(IFN-g) responses longitudinally (0, 3, 6, and 12 months post initiation of tuberculosis (TB)–HIV co-
treatment or ART alone) in 82 HIV-infected patients.
Results: Of the 65 evaluable participants, 30 were co-infected on ART, 17 were co-infected but not on
ART, and 18 were HIV-infected alone and on ART. In HIV-infected and HIV–TB-infected patients on ART,
IFN-g responses increased, whilst they decreased in those not on ART. However, baseline, month 3, and
month 6 IFN-g responses, irrespective of ART, did not differ in TB–HIV co-infected patients who culture-
converted compared to those who did not (1.25 vs. 1.05, p = 0.5 at baseline; 3.76 vs. 1.15, p = 0.2 for
month 3; 0.06 vs. 0.7, p = 0.3 for month 6). IFN-g levels did not correlate with the magnitude of sputum
bacillary load, smear status, or liquid culture time-to-positivity.
Conclusion: As IGRAs do not correlate with 2- or 6-month culture conversion or with markers of bacillary
burden, they are unlikely to be useful for the prognostication of treatment outcome in co-infected
patients.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
There is a desperate need for new tuberculosis (TB) diagnostics
and biomarkers to assist in new drug and vaccine development.
Presently, phase III clinical trials are conducted over a period of
30 to 60 months because it must be shown that a drug or drug
combination prevents or reduces treatment failure and relapse
(which requires a 24-month follow-up period).1 Recently it has
been suggested that a shorter follow-up may be possible, as studies* Corresponding author. Tel.: +27 21 4047650.
E-mail address: keertan.dheda@uct.ac.za (K. Dheda).
http://dx.doi.org/10.1016/j.ijid.2015.05.006
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).have shown that if patients were to relapse, they would do so
within 12 months of completion of anti-TB treatment (ATT).2,3
Similarly, vaccine studies suffer from a lack of biomarkers that can
predict a favourable response. Monitoring the TB treatment
response using sputum smear and culture poses problems, as
HIV-infected patients are frequently smear-negative4 and these
tests themselves are suboptimal predictors of outcome.5 More
recently, interferon gamma release assays (IGRAs) have become
available and have been investigated for use as diagnostics and
biomarkers of the TB treatment response and prognosis.6–27
Some studies have reported that IGRAs may be useful in
monitoring the TB treatment response,23,28 while others have
reported that most patients remain IGRA-positive after completionciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Figure 1. Patient ﬂow diagram. Of the 82 participants recruited, 11 (nine in the TB
arms (eight in TB–ART and one in the TB–no-ART group) and two in the non TB–ART
group) either withdrew consent or suffered a serious adverse event (SAE) and had to
be withdrawn from the study after recruitment. Six were excluded for incomplete
tests – missing month 3, or 6, or both QFT-GIT results. CD4 counts are in units of
cells/mm3. TB, tuberculosis; QFT-GIT, QuantiFERON-TB Gold In-Tube; ART,
antiretroviral therapy.
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studies have examined the utility of measuring longitudinal
interferon gamma (IFN-g) responses during the course of TB
treatment. They have mostly been conducted in predominantly
HIV-uninfected individuals12,21,30–32 and mainly in countries with
low TB and HIV burdens.11,33–35 Only two studies have used the
commercially available standardized QuantiFERON-TB Gold In-Tube
(QFT-GIT) assay in a setting with a high burden of TB and HIV.24,36
However, to our knowledge, no study has hitherto reported the
effects of antiretroviral therapy (ART) and/or ATT on quantitative
IFN-g responses in HIV–TB co-infected patients. There are also
hardly any data related to the effect of ART alone on such responses.
A further limitation is that several published studies, even from
Africa, have used non-standardized in-house IGRAs in an ELISA
format.16,37 Although there have been reports that IGRAs may
correlate with bacterial load in low-burden settings,38,39 this was
not the case in the only published report in patients from a high-
burden setting.40 There is therefore a need for more data from high-
burden settings, such as South Africa, where TB prevalence was
estimated to be between 0.4 million and 0.6 million cases in 2012.41
To address the deﬁciency in our knowledge about how T-cell
responses change during the course of therapy, the usefulness of
QFT-GIT in monitoring TB treatment responses was investigated
over a 1-year period in HIV-infected patients receiving standard
ATT with or without ART at primary care clinics in Durban, South
Africa. The inclusion of patients on ART makes this study important
in addressing this gap in the literature.
2. Methods
2.1. Participants
As part of a parent pharmacokinetic study, HIV-infected
patients aged 18–65 years were recruited between March
2007 and April 2008 after written informed consent was obtained.
These subjects included 62 newly diagnosed TB patients with
smear-positive disease who fell into three subgroups: (1) those
with a CD4 count <200 cells/mm3 who initiated ART as per
national guidelines (n = 20; henceforth referred to as TB–ART-
<200); (2) those with a CD4 count >200 cells/mm3 who initiated
ART (n = 21; henceforth referred to as TB–ART->200); and (3)
those with a CD4 T-cell count >200 cells/mm3 who did not initiate
ART (n = 21; henceforth referred to as TB–no-ART->200). Patients
without active TB disease (culture-negative) with a CD4 T-cell
count <200 cells/mm3 and who were initiated on ART were also
enrolled (n = 20; henceforth referred to as no-TB–ART-<200). The
different patient groups are shown in Figure 1. Inclusion and
exclusion criteria have been reported previously.42 The study was
approved by the Biomedical Research Ethics Committee of the
University of KwaZulu-Natal (E294/05) and was conducted in
accordance with International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) and South African Good Clinical Practice. All
subjects provided signed informed consent. This study is registered
at controlled-trials.com, ISRCTN77861053.
2.2. Recruitment and specimen collection
TB patients were enrolled if they were smear- and culture-
positive. Smear- and culture-negative non-TB patients were also
enrolled. Blood samples were drawn for the QFT-GIT (Cellestis Ltd,
Carnegie, Australia) assay at 0, 3, 6, and 12 months from all
participants enrolled. Sputum specimens were collected for smear
and culture at months 0, 2, 5, and 6 during TB treatment, and at
every follow-up visit (months 9, 12, 15, 18, and 24) if the patient
showed signs and symptoms of TB.2.3. Laboratory procedures
Sputum samples were processed using NALC/NaOH. Smear
microscopy was performed using both auramine and Ziehl–
Neelsen staining,43 and culture was done using Middlebrook
7H11 selective agar (Difco, Sparks, MD, USA) and Mycobacteria
Growth Indicator Tube (MGIT) liquid medium (Becton Dickenson
Biosciences Division, Sparks, MD, USA). The time to obtain a
positive result was recorded as the growth was observed; a
negative result was recorded if there was no growth at 42 days.
Positive cultures were conﬁrmed for Mycobacterium tuberculosis
complex using niacin and nitrate biochemical testing and tested for
susceptibility to antimicrobial agents using the proportion method
on Middlebrook 7H10 agar (Difco).
The QFT-GIT assay was performed according to the manufac-
turer’s instructions.44 QFT-GIT blood collection tubes, which
include a nil control tube, TB antigen tube, and an optional
mitogen tube, were incubated at 37 8C as soon as possible and
within 16 h of collection. Following a 16–24-h incubation period,
the tubes were centrifuged, the plasma removed, and the amount
of IFN-g measured by ELISA. The results were interpreted using
software supplied by the manufacturer. The result was consid-
ered as positive if the response to the speciﬁc antigens was 0.35
IU/ml, as negative if the response to the speciﬁc antigen was
<0.35 IU/ml and the IFN-g level of the positive control was 0.5
IU/ml, and as indeterminate if the value of both antigen-
stimulated samples was <0.35 IU/ml and the positive control
was <0.5 IU/ml.
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The sample size was that of convenience. All data were entered
using double data entry into an Epidata database and transferred to
Stata version 11 (StataCorp. 2009, College Station, TX, USA) for
statistical analysis. TB and non-TB patient characteristics were
compared using the Chi-square test for categorical variables and
the t-test for continuous variables. Median quantitative responses
of QFT-GIT were compared across subgroups at baseline using the
Wilcoxon rank sum test. Differences between baseline and 3 and
6 months were tested using a paired t-test and differences between
the subgroups tested using unpaired t-tests. Seventeen partici-
pants withdrew or were withdrawn from the study for various
reasons. The TB–ART CD4 >200 group (n = 10) and the TB–ART CD4
<200 group (n = 20) did not differ in their QFT responses at
baseline and follow-up and were thus combined.
3. Results
3.1. Participant characteristics
One thousand and thirty-four patients were pre-screened and
82 were enrolled in the study. Eighteen were excluded because of
World Health Organization (WHO) clinical stage 4 disease. Only
20 TB–HIV patients and 20 HIV-only patients with a CD4 count
below 200 cells/mm3were recruited and the rest had to have a CD4
count above 200 cells/mm3. Most exclusions were as a result of
failing to fulﬁl the CD4 count criterion. Of the 82 participants,
65 had at least three of the four time-point-speciﬁc QFT-GIT results
and were therefore analysed. There were no signiﬁcant differences
in the demographic and baseline characteristics between the three
groups (Table 1) with regard to age, sex, weight, height, body mass
index (BMI), and haemoglobin. There was no difference in the
mean viral load between the groups at baseline (p = 0.35).
Eight participants in arm 1 withdrew, three of whom completed
the pharmacokinetic study (PK), two were not ready to start ART,
two refused to provide a blood sample, and one had grade 4 amylase.
Three patients in arm 3 were withdrawn, one for grade 4 anaemia,
one refused to provide a blood sample, and the last had a repeat CD4
count above the enrolment threshold. In arm 2, four participants
were withdrawn: one refused to provide a blood sample and three
completed the PK but had missing QFT-GIT results on two or three
visits. Two participants in arm 6 died before month 6.Table 1
Characteristics of the patients included in the analysis
Demographic and clinical characteristics TB–ART 
CD4 <200 cells/mm3 CD4 >200 
(n = 20) (n = 10) 
Age, years, mean (SD) 36.2 (7.04) 29.4 (7.85
Sex, n (%)
Male 7 (35) 4 (40) 
Female 13 (65) 6 (60) 
Weight, kg, mean (SD) 56.1 (12.69) 54.5 (7.12
Height, m, mean (SD) 1.6 (0.09) 1.6 (0.11
BMI, kg/m2, mean (SD) 22.0 (4.52) 21.7 (3.73
BMI category, n (%)
Underweight 4 (20) 3 (30) 
Healthy 12 (60) 6 (60) 
Overweight 3 (15) 1 (10) 
Obese 1 (5) 0 (0) 
Haemoglobin, g/l, mean (SD) 10.1 (1.37) 11.2 (2.12
CD4 countb, cells/mm3, mean (SD) 113.6 (54.39) 304 (75.05
Viral load, log10 copies/ml, mean (SD) 5.2 (1.04) 4.9 (0.83
TB, tuberculosis; ART, antiretroviral therapy; SD, standard deviation; BMI, body mass i
a p-Values compare the two TB groups on ART.
b CD4 count: >200 category = 220–500.3.2. Baseline QFT-GIT results
Of the 82 participants enrolled, only four had indeterminate
results and only 65 had at least three sets of results; of these, only
one had an indeterminate result which was regarded as negative.
There were no signiﬁcant differences in mean baseline IFN-g levels
between the TB–ART and TB–no-ART groups (2.12 vs. 2.95 IU/ml,
p = 0.2) (Figure 2). There was a signiﬁcant difference between the
no-TB–ART and the TB–ART groups (0.95 vs. 2.12 IU/ml, p < 0.001)
and the no-TB–ART and the TB–no-ART groups (0.95 vs. 2.95 IU/ml,
p < 0.001). IFN-g levels were signiﬁcantly higher in the TB groups
(TB–ART and TB–no-ART) when compared to the no-TB–ART group
(1.15 vs. 0.24 IU/ml; p < 0.001). The correlation between IFN-g
levels and CD4 counts for all groups (TB and no-TB) was positive
(rs = 0.26, p = 0.02). The median baseline IFN-g levels also differed
signiﬁcantly when stratiﬁed by CD4 count group (CD4 <200: 0.7
(interquartile range (IQR) 0.05–2.0) vs. CD4 >200: 2.0 (IQR 0.7–
4.4), p = 0.02). However, among the TB patients alone, the
Spearman correlation between IFN-g and CD4 count was still
positive (rs = 0.15) but no longer reached statistical signiﬁcance
(p = 0.30). The subsequent comparison of median QFT-GIT
responses stratiﬁed by CD4 count in the TB group only was not
signiﬁcant (CD4 <200: 1.1 (IQR 0.7–2.5) IU/ml vs. >200: 2 (IQR
0.7–4.4) IU/ml, p = 0.40). Because there was no difference in the
baseline IFN-g in the two TB–ART groups, the results were pooled.
3.3. IFN-g levels and bacillary load correlates at diagnosis
There was no correlation between IFN-g levels and time to
positivity (rs = 0.09, p = 0.90; Figure 3, panel A). The association
between sputum bacillary load as measured by smear grade and
IFN-g levels was not signiﬁcant (Figure 3, panel B). IFN-g levels did
not correlate signiﬁcantly with increasing smear grade (p = 0.45).
3.4. Proportion QFT-GIT-positive at different time-points by group
(Figure 4)
The percentage of QFT-GIT-positive patients in the TB–no-ART
group between month 0 (81%) and months 3 (56%), 6 (50%), and 12
(46%) was not signiﬁcantly different (p = 0.10, 0.07, and 0.06,
respectively, for comparisons for each time-point relative to the
baseline). The pattern was similar in the TB–ART group between
month 0 (80%) and month 3 (73%) (p = 0.50); however signiﬁcantTB–no-ART No-TB–ART
cells/mm3 p-Valuea CD4 >200 cells/mm3 CD4 <200 cells/mm3
(n = 17) (n = 18)
) 0.02 29.6 (5.40) 35.5 (6.73)
0.8 11 (65) 8 (44)
6 (35) 10 (56)
) 0.8 57 (11.94) 62.8 (11.58)
) 0.9 1.6 (0.11) 1.6 (0.11)
) 0.9 22.4 (5.34) 25.3 (6.13)
2 (12) 2 (11)
13 (76) 8 (44)
0.9 0 (0) 3 (17)
2 (12) 5 (28)
) 0.3 11.1 (1.52) 11.0 (1.66)
) <0.001 331.9 (78.76) 120.3 (51.66)
) 0.2 4.7 (1.08)
ndex.
Figure 2. Baseline interferon gamma (IFN-g) levels.
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6 (54%) and 12 (50%) (p = 0.04 and 0.02, respectively). When the
proportion of QFT-GIT-positive in the no-TB–ART group at baseline
(26%) was compared to months 3 (68%), 6 (67%), and 12 (76%), anFigure 3. Panel A: Relationship between interferon gamma (IFN-g) responses and
bacillary load and time to positivity at baseline. Panel B: There were no scanty
results. +, positive; ++, 2+ positive and +++, 3+ positive; TTP, time to positivity; IFN-
g, interferon gamma.increased proportion of individuals were positive (p = 0.01, 0.02,
and 0.004, respectively).
3.5. The effect of ART on IFN-g responses (Figures 5 and 6)
3.5.1. Change between month 0 and month 3
With regard to changes in median IFN-g responses depending
on ART or not, irrespective of TB culture status at baseline
(Figures 5 and 6), TB–ART participants (n = 30) had an IFN-g
median response at months 0 and 3 of 1.05 vs. 3.76 IU/ml and a
per-patient median increase of 0.015 (IQR 0.22 to 2.4, p = 0.07).
In TB–no-ART participants (n = 17), IFN-g median responses
were 2.1 and 0.895 IU/ml for these time-points and there was a
per-patient median decrease of 0.27 (IQR 2.4 to 2.4, p = 0.50).
In no-TB–ART participants (n = 18), the IFN-g median response
was 0.14 vs. 1.7 IU/ml and there was a median increase of 0.98
(IQR 0–7, p = 0.004). Figure 7 shows the per-patient variation in
QFT-GIT changes, with the participants receiving ART showing
more elevations and those not receiving ART showing more
declines.
3.5.2. Change between month 0 and month 6
There was no change in median IFN-g responses from month
0 to month 6 in the TB–ART group. IFN-g responses were 1.05 vs.
0.7 IU/ml and there was a median per-patient decrease of 0.11 (IQR
0.65 to 0.19, p = 0.30). In the TB–no-ART group, the IFN-g median
response was 2.1 vs. 0.47 IU/ml and there was a median per-
patient decrease of 0.27 (IQR 2.2 to 0.75, p = 0.20). In the no-TB–
ART group, the IFN-g median response was 0.15 vs. 1.5 IU/ml and
there was a median per-patient increase of 0.63 (IQR 0–2.6,
p = 0.008).
3.5.3. Change between month 0 and month 12
The only signiﬁcant changes were in the no-TB–ART group, with
a median IFN-g of 0.14 vs. 1.25 IU/ml and a median per-patient
increase of 0.95 (IQR 0–7, p = 0.03). The rest of the changes were
similar to those between months 0 and 6.
3.6. Longitudinal changes in IFN-g responses
The change in IFN-g responses from baseline through to month
12 varied extensively, although in general there was a decline from
months 6 to 12. In the groups receiving ART, for participants with
high baseline levels (2.0 and above), there was a steady decline to
month 12. For participants with lower levels (below 2), there was a
sharp increase in IFN-g levels at month 3, followed by a sharp
decline at month 6 and a steadier decline to month 12, which was
seen less in the group not receiving ART.Figure 4. Proportion of patients with a QuantiFERON-TB Gold In-Tube result >0.35
IU/ml by group.
Figure 5. Longitudinal interferon gamma (IFN-g) responses at different time-
points. Longitudinal IFN-g responses are shown for patients undergoing ATT
(n = 17) and those undergoing TB treatment and ART (n = 30) at 0, 3, 6, and
12 months, as well as for non-TB patients on ART (n = 18). ATT, anti-TB treatment;
ART, antiretroviral therapy.
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responses
Median IFN-g responses from months 0, 3, and 6 irrespective of
ART did not differ between TB participants who culture-converted
at month 2 and those who did not: 1.25 vs. 1.05, 3.76 vs. 1.15, and
0.06 vs. 0.7, respectively. Median IFN-g responses from months 0,
3, and 6 did not differ signiﬁcantly between the no-TB–ART
participants who remained culture-negative versus those who
converted to positive: 0.15 vs. 0.47, 1.73 vs. 1.6, and 2 vs. 0,
respectively. Only three participants remained culture-positive
(either solid or liquid) at month 6 (reduction from 1.12 to 0.06 IU/
ml; p = 0. 02). All other participants in the TB and no-TB–ART
groups were culture-negative at month 6. Four previously smear-
and culture-negative participants (no-TB group) converted toFigure 6. Individual participant changes in interferon gamma (IFN-g) responses over tim
between 0, 3, 6, and 12 months: TB patients on ART, n = 30; TB patients not receiving culture-positive at month 2 (MGIT or 7H11) with a median IFN-g
increase from 0.47 to 1.6 IU/ml (p = 0.08); three received ATT. Two
participants were culture-positive at month 6 and both received
ATT; IFN-g declined from 0.15 to 0 IU/ml. When the ‘grey zone’
criterion (0.2–0.7 IU/ml) was applied,45 of the 18 no-TB–ART
participants, nine had baseline QFT-GIT <0.2, of whom three
remained below 0.2 at month 3 and six increased to above 0.7. Two
remained below 0.2 at month 6, two increased to the ‘grey zone’,
and ﬁve increased to above 0.7. Five were in the ‘grey zone’ at
baseline: two increased to >0.7 by month 3 and were treated
(culture-positive) and three remained in the ‘grey zone’ (not
treated). Four participants were >0.7 at baseline and remained
>0.7 at months 3 and 6 (one treated from culture results). Patients
were not treated if no bacterial evidence existed.
4. Discussion
There are limited or no data related to how quantitative RD-1-
speciﬁc T-cell responses change during the course of treatment
(ART or TB treatment) in HIV–TB co-infected persons. There are
also hardly any data on how such responses correlate with
microbiological readouts in patients on TB treatment, whether
HIV-infected or not. The key ﬁndings of this study were the
following: (1) overall, although T-cell responses generally declined
with ATT, IFN-g responses (magnitude or reversion) did not
correlate with studies of bacterial load at diagnosis, or with culture
conversion at 2 to 3 months post treatment initiation; (2) in
contrast to TB treatment alone, ART in HIV–TB co-infected persons
caused a transient increase in T-cell responses, which then fell over
time to levels similar to patients not receiving ART; and (3) ART
alone in HIV-infected persons without TB resulted in a gradual
increase in T-cell responses over several months. Thus, ART must
be taken into account when evaluating T-cell responses (e.g., IGRA,
and by inference the tuberculin skin test (TST)) in HIV-infected
persons, irrespective of whether they are on TB treatment, and
although such responses generally decline with ATT, there is no
correlation with 2-month culture conversion readouts.e (spaghetti plots). Longitudinal changes in QFT-GIT between 0 and 3 months and
ART, n = 17; non-TB patients on ART, n = 18.
Figure 7. Median changes in interferon gamma (IFN-g) responses at different time-points. Median change with error bars for three groups: no-TB–ART, TB–ART, and TB–no-
ART.
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which were obtained from studies conducted in a high-burden
setting, reporting the correlation of serial antigen-speciﬁc T-cell
responses/IGRAs with bacterial load.40,46 Thus, with the exception
of this report and the ﬁndings reported here, studies from either
low- or high-burden settings have not previously reported the
correlation of IGRA responses with measures of mycobacterial
burden.8,12,13,16,18,20–23,26,28,32,37,47,48 Although culture conversion
in itself has a suboptimal predictive value for a favourable
treatment response, the lack of any correlation, and no difference
in the magnitude of IGRA responses in microbiologically positive or
negative persons, makes it unlikely that IGRAs will be useful as
treatment monitoring tools or prognostic markers in HIV–TB co-
infected persons (or uninfected persons with TB for that matter).
The lack of correlation is not surprising because antigen-speciﬁc
memory T-cell readouts cannot distinguish between exposure,
latent infection, and active TB.14,49
In contrast to TB treatment alone, ART in TB–HIV co-infected
persons caused a transient spike in T-cell responses followed by a
declining response thereafter, and this pattern was independent of
CD4 count (though ostensibly more robust in those with a CD4
count of less than 200 cells/mm3). This is, to our knowledge, the
ﬁrst report of how serial IGRA responses change in HIV–TB co-
infected patients on ART versus no ART. The cause of the transient
increase in responses is unclear, but factors likely to be important
include: (1) immune reconstitution due to the treatment of TB
itself (down-regulation of an anti-inﬂammatory response driven
by cytokines such as interleukin 10 and cell types including
regulatory T-cells),49,50,51 (2) the immune reconstitution effect of
ART, which causes the redistribution of effector memory T-cells to
the blood compartment, and (3) release of TB antigen consequent
upon treatment, which may augment T-cell responses. The lack of
this spike-like response in the HIV–TB without ART group suggests
that ART is the major driver of this phenomenon. TB immune
reconstitution inﬂammatory syndrome (TB-IRIS) is also associated
with exaggerated cytokine responses, including antigen-speciﬁc
Th1 responses, although there was no difference in participants on
TB treatment and ART who had TB-IRIS versus those who did not.52
These observations have important implications for the interpre-
tation of serial IGRA responses in HIV-infected persons. The
treatment of presumed latent TB infection in children resulted in a
similar transient exaggerated response.34
ART alone (without active TB) resulted in a signiﬁcant increase
in IGRA responses by month 3. This is likely due to ART-relatedimmune reconstitution and the redistribution of effector memory
T-cells back into the blood compartment.53 Similarly, ART can
cause apparent conversion of the TST whereby TST-negative
persons become TST-positive on ART.54,55 These data have
important implications for the interpretation of immunodiagnostic
tests in the context of isoniazid preventive therapy (IPT) provision
in high-burden settings, as current data suggest that only TST-
positive persons are likely to beneﬁt from IPT.56,57
There are several limitations to this work, including the small
number of patients and the fact that QFT-GIT is not the most
suitable test for measuring IFN-g. However, although there was a
decline in evaluable participants due to deaths and withdrawals,
and the number of participants without complete results for all
time-points decreased, there was still sufﬁcient data to show
interesting information on the effects of concomitant TB–HIV
treatment, and much needed data related to its impact on serial
IGRA responses are provided. This study further sheds light on the
impact of the CD4 count in this context (although the study was
conducted during a time when newer and more effective ART was
unavailable within the national treatment programme). However,
even with this limited dataset that had limited power, no trend or
relationship between bacillary load at diagnosis and IFN-g
reversion (0 to 3 months) or sputum culture conversion could
be shown. It should be borne in mind that the predictive value of
culture conversion itself for a long-term favourable outcome
(failure or relapse at 2 years) is suboptimal.58 However, the lack of
correlation of initial and serial IGRAs with bacterial load and the
high proportion of HIV–TB cases remaining IGRA-positive at 6 and
12 months post treatment makes it unlikely that it would make a
good marker of treatment response. Chiappini et al. concluded that
monitoring IGRA changes over time seems to have only speculative
value in adults.35 This meta-analysis, however, did not differenti-
ate between those who were on concurrent ART and no ART.
In conclusion, these preliminary data suggest that although QFT-
GIT readouts decreased with time during ATT, irrespective of
whether participants were on ART, they did not correlate with 2- or
6-month culture conversion and markers of bacillary burden.
Therefore, IGRAs do not appear to be useful for the prognostication of
treatment outcome in co-infected patients on concurrent therapy.
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